Rallybio Corporation - RLYB Company profit before taxes, interest and amortization
Rallybio Corporation (RLYB) developments against neonatal thrombocytopenia are undergoing clinical trials supported by a stable liquidity reserve. Operating cash flow before interest and taxes demonstrates profit dynamics, where 0.00 is the current value of the indicator. The pricing power for orphan drugs is maintained by strict FDA control and patent protection, creating insurmountable barriers to entry for new players.
Summary analytical data breakdowns for Rallybio (RLYB)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Rallybio Corporation|RLYB - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Rallybio Corp|RLYB - Company Aggregate Debts|Debts to Book Capitalization Rallybio|RLYB - Company Long-Term Debt|Company Short-Term Debt Rallybio|Quick Liquidity rallybio.com
- earnings and market ratios statistics:
RLYB - Net Income|Expected Net Profit Rallybio Corporation|RLYB - P/E Multiple|Future Price to Earnings Rallybio Corp|RLYB - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Rallybio|RLYB - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Rallybio|RLYB - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months rallybio.com|RLYB - Earnings growth in current year|Expected earnings per share growth for next year Rallybio Corporation
- sales revenue and business income indicators:
Summary company analytics:RLYB (Rallybio Corporation)
This indicator captures the actual cash flow generated by core operations before deducting financial obligations and taxes, reflecting the business's ability to self-fund its expenses. Continuous monitoring of EBITDA allows for an assessment of the financial stability of Rallybio Corporation (RLYB), where the operating flow is primarily driven by grants for the development of innovative drugs for the therapy of rare pathologies.
Competitors of Rallybio Corporation (RLYB)
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|Income before deduction of interest, taxes and amortization ANIP|MannKind Corp. - Operating profit EBITDA|AMPH - Operating profit EBITDA|Pacira BioSciences (PCRX) - Profit before payment of interest, taxes and amortization|SPRY (ars-pharma.com) - Profit before payment of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Theravance Biopharma, Inc.|Profit before payment of interest, taxes and amortization AQST|Operating profit before deduction of amortization SCPH (scPharmaceuticals Inc.)|TECX - Profit before interest, taxes and amortization|Operating profit EBITDA TNXP (Tonix Pharmaceuticals)|SXT Pharmaceuticals - Profit before payment of interest, taxes and amortization|Eupraxia Pharma - Operating profit EBITDA|Operating income before deduction of amortization BioHarvest Sciences, Inc. BHST|Invizyne Technologies, Inc. (EXOZ) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Oramed Pharmaceuticals Inc. (ORMP)|Operating profit before deduction of amortization ENTX|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Operating profit before deduction of amortization Cumberland Pharmaceuticals Inc CPIX|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|FibroGen Corporation (FGEN) - Profit before interest, taxes and amortization|TELO - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RANI (Rani Therapeutics)|synergychc.com (SNYR) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization LEXX (Lexaria Bioscience Corp.)|Profit before payment of interest, taxes and amortization Pulmatrix Corp|Profit before interest, taxes and amortization Pheton PTHL|Profit before payment of interest, taxes and amortization Aptorum Group Limited (APM)|LYRA (lyratherapeutics.com) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA IBO (Impact BioMedical)|Operating profit EBITDA TNF Pharmaceuticals Inc. TNFA|YCBD: Operating profit before deduction of amortization|PainReform Corp - Company profit before taxes, interest and amortization|CYTO: Operating profit EBITDA|LIPO - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization OptiNose|Profit before interest, taxes and amortization Pieris Pharmaceuticals Inc PIRS|Profit before payment of interest, taxes and amortization Procaps Group SA (PROC)|Petros Pharma - Operating profit before amortization|Profit before payment of interest, taxes and amortization Qilian International QLI|Income before deduction of interest, taxes and amortization SLRN|TFFP - Profit before payment of interest, taxes and amortization
